Investment Firm Raises Price Target For Major Biotech Company
Mizuho Boosts MiMedx Group's Price Target to $14, Continues Bullish Outlook.
In a recent move that underscores their confidence in the regenerative medicine sector, Mizuho Securities has maintained its 'Buy' rating on MiMedx Group Inc. (NASDAQ: MDXG) and has raised the price target from a previous estimate to $14. This comes as the company continues to make significant strides in its advanced wound care and surgical tissue solutions. $MiMedx (MDXG.US)$
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
